Immune Response after SARS-CoV-2 Infection with Residual Post-COVID Symptoms.
Tanyaporn PongkunakornThamonwan ManosanApinya SurawitSuphawan OphakasPichanun MongkolsucharitkulSureeporn PumeiamSophida SutaBonggochpass PinsawasNitat SookrungNawannaporn SaelimKodchakorn MahasongkramPannathee PrangtawornAnchalee TungtrongchitrWatip TangjittipokinSuthee MangmeeKorbporn BoonnakTassanee NarkdontriNipaporn TeerawattanapongRungsima WanitphadeedechaKorapat MayurasakornPublished in: Vaccines (2023)
Many patients develop post-acute COVID syndrome (long COVID (LC)). We compared the immune response of LC and individuals with post-COVID full recovery (HC) during the Omicron pandemic. Two hundred ninety-two patients with confirmed COVID infections from January to May 2022 were enrolled. We observed anti-SARS-CoV-2 receptor-binding domain immunoglobulin G, surrogate virus neutralization test, T cell subsets, and neutralizing antibodies against Wuhan, BA.1, and BA.5 viruses (NeuT). NeuT was markedly reduced against BA.1 and BA.5 in HC and LC groups, while antibodies were more sustained with three doses and an updated booster shot than ≤2-dose vaccinations. The viral neutralization ability declined at >84-days after COVID-19 onset (PC) in both groups. PD1-expressed central and effector memory CD4 + T cells, and central memory CD8 + T cells were reduced in the first months PC in LC. Therefore, booster vaccines may be required sooner after the most recent infection to rescue T cell function for people with symptomatic LC.
Keyphrases
- sars cov
- coronavirus disease
- respiratory syndrome coronavirus
- immune response
- simultaneous determination
- end stage renal disease
- mass spectrometry
- inflammatory response
- newly diagnosed
- peritoneal dialysis
- toll like receptor
- regulatory t cells
- solid phase extraction
- prognostic factors
- sleep quality
- liver failure
- intensive care unit
- zika virus
- type iii
- extracorporeal membrane oxygenation
- high resolution mass spectrometry